StoneSmart
In this video, Juan Calle, MD, of Cleveland Clinic, explains what he would tell a young urologist who wants to become an expert in stone prevention and minimizing recurrence.
In this video, Juan Calle, MD, of Cleveland Clinic, explains what he would tell a young urologist who wants to become an expert in stone prevention and minimizing recurrence.
Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
Benjamin M. Brucker, MD, outlines considerations surrounding pre-procedure urinalysis, prophylactic periprocedural antibiotics, and optimal dosing regimens for onabotA administration.
Among the content is additional information on types of urinary incontinence, ways to control urgency, and frequently asked questions about a healthy bladder.
The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.
According to Daniel D. Joyce, MD, MS, policy initiatives should focus on improving the value and efficiency of radiation.
Justin M. Dubin, MD, outlines the current ways that artificial intelligence is being used in the male infertility space.
According to the company, the MHRA approval represents the first marketing approval outside the US for NAI.
Anne K. Schuckman, MD, discusses some of the current challenges in delivering optimal care for patients with non–muscle invasive bladder cancer.
Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks.
For the trial, a biomarker will be utilized to aid in patient selection for the treatment.